small molecule

AUVELITY

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

Loss of exclusivityNovember 2043latest FDA-listed patent expiry
CompanyAxsome Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameAUVELITY
Active ingredientBUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
Strength105MG;45MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2022
Marketing statusRX

Listed patents

PatentExpiresType
12653795November 2043use U-4516
11844797April 2043use U-3778
12194036April 2043use U-4521
11839612March 2043use U-3419
12472155February 2043use U-4519
11752144February 2043use U-3419
12146889February 2043use U-3419
12042473February 2043use U-3419
12036191February 2043use U-3419
11986444February 2043use U-3419
12370154February 2043use U-4518
12599576February 2043use U-4518
11730706January 2043use U-3419
12194005January 2043use U-4523
11883373January 2043use U-3419
12364674January 2043use U-4516
12678506January 2043product
12357697January 2043use U-3419
11925636January 2043use U-3419
11717518January 2043use U-3419
12156914January 2043product
12661408January 2043use U-3419
12239642January 2043use U-4515
12472174January 2043use U-4515
12263161January 2043use U-4515
12564587January 2043use U-4515
12478622January 2043use U-4515
12310961January 2043use U-3419
12390428December 2041use U-3419
11896563December 2041use U-3419
12576078June 2040use U-4516
12472156June 2040use U-4516
12433884June 2040use U-4514
10940124January 2040use U-3419
10925842January 2040use U-3419
10966942January 2040use U-3419
10780064January 2040use U-3419
10894047November 2034use U-3419
10064857November 2034use U-4517
11291665November 2034use U-4517
10780066November 2034use U-4517
11291638November 2034use U-4517
10786469November 2034use U-3419
11253492November 2034use U-4526
10881657November 2034use U-3419
10874663November 2034use U-3419
10799497November 2034use U-3419
11058648November 2034use U-3419
11273133November 2034use U-4526
10864209November 2034use U-3419
10806710November 2034use U-4517
10881624November 2034use U-4517
10786496November 2034use U-4517
11020389November 2034use U-3419
11185515November 2034use U-3419
10945973November 2034use U-3419
11285146November 2034use U-4517
11285118November 2034use U-4526
10596167November 2034use U-4517
11439636November 2034use U-4517
9314462November 2034use U-4517
9198905November 2034use U-4520
11426401November 2034use U-4517
11426370November 2034use U-4526
11419867November 2034use U-4517
10772850November 2034use U-3419
11273134November 2034use U-4517
11253491November 2034use U-3419
11234946November 2034use U-4526
10548857November 2034use U-3419
11229640November 2034use U-3419
10874665November 2034use U-3419
10933034November 2034use U-3419
10251879November 2034use U-4517
10092561November 2034use U-4517
10894046November 2034use U-3419
11191739November 2034product
10874664November 2034use U-3419
10080727November 2034use U-4520
11197839November 2034product
11147808November 2034use U-3419
11207281November 2034use U-4537
11141416November 2034use U-3419
11141388November 2034use U-3419
11213521November 2034use U-3419
11123343November 2034use U-3419
10966974November 2034use U-3419
10512643November 2034use U-4517
10463634November 2034use U-4517
10105361November 2034use U-4522
10105327November 2034use U-3419
10092560November 2034use U-4517
9968568November 2034use U-4517
11969421November 2034use U-3419
11590124November 2034use U-4526
11576909November 2034use U-4526
11571417November 2034use U-4526
11123344November 2034use U-4517
11065248November 2034use U-4517
11478468November 2034use U-3419
11541048November 2034use U-3419
11541021November 2034use U-3419
11534414November 2034product
11779579November 2034use U-3419
11617728November 2034use U-3419
11617747November 2034use U-4526
11596627November 2034use U-3419
11497721November 2034use U-3419
12109178November 2034use U-3419
11007189November 2034use U-4516
11129826November 2034use U-3419
11524008November 2034use U-3419
11524007November 2034use U-3419
11517542November 2034use U-3419
11517543November 2034use U-3419
11510918November 2034use U-3419
11382874November 2034use U-4517
11364233November 2034use U-3419
9457025November 2034use U-4517
10058518November 2034use U-4522
9278095November 2034use U-4517
9867819November 2034use U-4517
9168234November 2034use U-4517
9861595November 2034use U-4517
9700553November 2034use U-4517
11357744November 2034use U-4517
11344544November 2034use U-4517
9486450November 2034use U-4517
9474731November 2034use U-4520
9375429November 2034use U-4517
9421176November 2034use U-4517
9408815November 2034use U-4517
9763932November 2034use U-4517
11311534November 2034use U-3419
9205083November 2034use U-4520
9707191November 2034use U-4522
10898453November 2034use U-3419
11433067November 2034product
9700528November 2034use U-4517
9370513November 2034use U-4520
9457023November 2034use U-4517
9238032November 2034use U-4520
11096937November 2034use U-3419
11298352November 2034use U-4517
10966941November 2034use U-4517
11298351November 2034use U-3419
11090300November 2034use U-3419
8569328July 2032product

Regulatory exclusivity

CodeExpires
I-913April 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.